PERTH, Australia – Brisbane, Australia-based Factor Therapeutics Ltd. is stopping all development of VF-001 after a phase II trial in venous leg ulcer healing failed to meet all endpoints, which included reduction in wound size, proportion of patients with ulcers fully healed and time to achieve full wound healing.
PERTH, Australia – Australia is rolling out a nationwide electronic health record (EHR) portal, called My Health Record under which patients will be able to access their health data any time and take the information with them when they move.
PERTH, Australia – Australia is rolling out a nationwide electronic health record (EHR) portal, called My Health Record under which patients will be able to access their health data any time and take it with them when they move.
PERTH, Australia – Australian regenerative medicine company Mesoblast Ltd.'s allogeneic cell therapy candidate, MPC-150-IM, failed to meet the primary endpoint in a phase IIb trial in end-stage heart failure patients implanted with a left ventricular assist device (LVAD), but it delivered meaningful clinical results that may make it approvable.
PERTH, Australia – Australian regenerative medicine company Mesoblast Ltd.'s allogeneic cell therapy candidate, MPC-150-IM, failed to meet the primary endpoint in a phase IIb trial in end-stage heart failure patients implanted with a left ventricular assist device (LVAD), but it delivered meaningful clinical results that may make it approvable.
PERTH, Australia – Australia's Cochlear Ltd. said it would fight a U.S. District Court patent infringement verdict reported Monday that doubles the damages Cochlear was ordered to pay the Alfred E. Mann Foundation for Scientific Research and Advanced Bionics LLC. The Federal District Court for the Central District of California awarded "enhanced damages" in the amount of $268 million, and the cochlear implant company will need to lodge a $335 million insurance bond to appeal the judgement.
